CONTEXT: Adiponectin, synthesized by adipocytes, has been shown to be a predictor of type 2 diabetes. Adiponectin circulates in plasma as three oligomeric isoforms. High-molecular-weight (HMW) adiponectin is thought to be the most biologically active form of adiponectin in terms of glucose homeostasis. OBJECTIVE: Our objective was to investigate whether HMW adiponectin is more strongly associated with incident diabetes than is total adiponectin. DESIGN: A nested case-cohort study was conducted in a population-based cohort of 9740 middle-aged, initially healthy, white and African-American participants of the Atherosclerosis Risk in Communities (ARIC) study followed for up to 9 yr. Plasma total and HMW adiponectin were measured by ELISA in 550 incident diabetes cases and 540 noncases. RESULTS: Overall hazard ratios (95% confidence intervals) for developing diabetes for those in the fourth (vs. the first) quartile of total adiponectin, HMW adiponectin, and the ratio of HMW to total were 0.40 (0.25-0.64), 0.38 (0.23-0.63), and 0.65 (0.42-0.99), respectively, after adjustment for age, sex, ethnicity, study center, parental history of diabetes, hypertension, body mass index, and waist-to-hip ratio and 0.52 (0.32-0.85), 0.51 (0.31-0.86), and 0.77 (0.50-1.20), respectively, after additional adjustment for inflammation score (a score composed of six inflammation markers) and fasting insulin. When further adjusting for baseline fasting glucose, the graded associations were attenuated substantially and lost their gradation. CONCLUSIONS: In this community-based sample of U.S. adults, higher total and HMW adiponectin concentrations were similarly associated with a lower incidence of diabetes over 9 yr of follow-up.
CONTEXT: Adiponectin, synthesized by adipocytes, has been shown to be a predictor of type 2 diabetes. Adiponectin circulates in plasma as three oligomeric isoforms. High-molecular-weight (HMW) adiponectin is thought to be the most biologically active form of adiponectin in terms of glucose homeostasis. OBJECTIVE: Our objective was to investigate whether HMW adiponectin is more strongly associated with incident diabetes than is total adiponectin. DESIGN: A nested case-cohort study was conducted in a population-based cohort of 9740 middle-aged, initially healthy, white and African-American participants of the Atherosclerosis Risk in Communities (ARIC) study followed for up to 9 yr. Plasma total and HMW adiponectin were measured by ELISA in 550 incident diabetes cases and 540 noncases. RESULTS: Overall hazard ratios (95% confidence intervals) for developing diabetes for those in the fourth (vs. the first) quartile of total adiponectin, HMW adiponectin, and the ratio of HMW to total were 0.40 (0.25-0.64), 0.38 (0.23-0.63), and 0.65 (0.42-0.99), respectively, after adjustment for age, sex, ethnicity, study center, parental history of diabetes, hypertension, body mass index, and waist-to-hip ratio and 0.52 (0.32-0.85), 0.51 (0.31-0.86), and 0.77 (0.50-1.20), respectively, after additional adjustment for inflammation score (a score composed of six inflammation markers) and fasting insulin. When further adjusting for baseline fasting glucose, the graded associations were attenuated substantially and lost their gradation. CONCLUSIONS: In this community-based sample of U.S. adults, higher total and HMW adiponectin concentrations were similarly associated with a lower incidence of diabetes over 9 yr of follow-up.
Authors: Bruce B Duncan; Maria Inês Schmidt; James S Pankow; Heejung Bang; David Couper; Christie M Ballantyne; Ron C Hoogeveen; Gerardo Heiss Journal: Diabetes Date: 2004-09 Impact factor: 9.461
Authors: Utpal B Pajvani; Xueliang Du; Terry P Combs; Anders H Berg; Michael W Rajala; Therese Schulthess; Jürgen Engel; Michael Brownlee; Philipp E Scherer Journal: J Biol Chem Date: 2002-12-20 Impact factor: 5.157
Authors: Robert S Lindsay; Tohru Funahashi; Robert L Hanson; Yuji Matsuzawa; Sachiyo Tanaka; P Antonio Tataranni; William C Knowler; Jonathan Krakoff Journal: Lancet Date: 2002-07-06 Impact factor: 79.321
Authors: Bruce B Duncan; Maria Inês Schmidt; James S Pankow; Christie M Ballantyne; David Couper; Alvaro Vigo; Ron Hoogeveen; Aaron R Folsom; Gerardo Heiss Journal: Diabetes Date: 2003-07 Impact factor: 9.461
Authors: K M Choi; J Lee; K W Lee; J A Seo; J H Oh; S G Kim; N H Kim; D S Choi; S H Baik Journal: Clin Endocrinol (Oxf) Date: 2004-07 Impact factor: 3.478
Authors: T Yamauchi; J Kamon; H Waki; Y Terauchi; N Kubota; K Hara; Y Mori; T Ide; K Murakami; N Tsuboyama-Kasaoka; O Ezaki; Y Akanuma; O Gavrilova; C Vinson; M L Reitman; H Kagechika; K Shudo; M Yoda; Y Nakano; K Tobe; R Nagai; S Kimura; M Tomita; P Froguel; T Kadowaki Journal: Nat Med Date: 2001-08 Impact factor: 53.440
Authors: Unab I Khan; Dan Wang; Maryfran R Sowers; Peter Mancuso; Susan A Everson-Rose; Philipp E Scherer; Rachel P Wildman Journal: Metabolism Date: 2012-03-22 Impact factor: 8.694
Authors: Leticia M Nogueira; Christina C Newton; Michael Pollak; Debra T Silverman; Demetrius Albanes; Satu Männistö; Stephanie J Weinstein; Eric J Jacobs; Rachael Z Stolzenberg-Solomon Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-01-17 Impact factor: 4.254
Authors: S Mirza; Monir Hossain; Christine Mathews; Perla Martinez; Paula Pino; Jennifer L Gay; Anne Rentfro; Joseph B McCormick; Susan P Fisher-Hoch Journal: Cytokine Date: 2011-10-28 Impact factor: 3.861
Authors: Hyon-Suk Kim; Jaeseong Jo; Jung Eun Lim; Young Duk Yun; Soo Jin Baek; Tae-Yong Lee; Kap Bum Huh; Sun Ha Jee Journal: Endocrine Date: 2013-02-06 Impact factor: 3.633